Compass Therapeutics, Inc. (CMPX) cash on hand
Compass Therapeutics, Inc. (CMPX) held cash of $208.91M at the end of fiscal 2025 (December 31, 2025). That is 64.9% higher than the $126.72M of fiscal 2024. Figures as of 18 Nov 2026, 12:34 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- Cash, fiscal 2025
- $208.91M
- Change on fiscal 2024
- +64.9%
- Highest on record
- $208.91Mfiscal 2025
- Lowest on record
- $126.72Mfiscal 2024
- Fiscal years on record
- 42022–2025
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.
Compass Therapeutics, Inc. cash on hand, in more detail
Across the 4 fiscal years on record (2022–2025), the highest was $208.91M in fiscal 2025 and the lowest $126.72M in fiscal 2024.
Cash by fiscal year
Compass Therapeutics, Inc. cash on hand, year by year
| Fiscal year | Cash | Change | Year ended |
|---|---|---|---|
| 2025 | $208.91M | 64.9% up | |
| 2024 | $126.72M | 16.9% down | |
| 2023 | $152.46M | 18.3% down | |
| 2022 | $186.61M | — |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Cash is the cash, cash equivalents and short-term investments on the balance sheet at the fiscal year-end, shown for the fiscal years the market data feed covers because the older SEC record counts cash and equivalents alone.
How to read it
Cash is the cushion that pays for bad years, buybacks and acquisitions; compare it with total debt to see whether the company is a net borrower.
Compass Therapeutics, Inc., figure by figure
- Compass Therapeutics, Inc. market cap
- Compass Therapeutics, Inc. revenue
- Compass Therapeutics, Inc. earnings
- Compass Therapeutics, Inc. earnings per share (EPS)
- Compass Therapeutics, Inc. P/E ratio
- Compass Therapeutics, Inc. P/S ratio
- Compass Therapeutics, Inc. P/B ratio
- Compass Therapeutics, Inc. free cash flow
- Compass Therapeutics, Inc. operating margin
- Compass Therapeutics, Inc. dividend
- Compass Therapeutics, Inc. shares outstanding
- Compass Therapeutics, Inc. total debt
- Compass Therapeutics, Inc. total assets
- Compass Therapeutics, Inc. return on equity (ROE)
- Compass Therapeutics, Inc. return on invested capital (ROIC)
Compass Therapeutics, Inc. (CMPX) overview: price, valuation and scorecard
Compass Therapeutics, Inc. cash on hand: questions and answers
How much cash does Compass Therapeutics, Inc. have?
Compass Therapeutics, Inc. (CMPX) held cash of $208.91M at the end of fiscal 2025 (December 31, 2025). That is 64.9% higher than the $126.72M of fiscal 2024.
What are the highest and lowest cash figures on record for Compass Therapeutics, Inc.?
Across the 4 fiscal years on record (2022–2025), the highest was $208.91M in fiscal 2025 and the lowest $126.72M in fiscal 2024.
How is Compass Therapeutics, Inc.'s cash calculated?
Cash is the cash, cash equivalents and short-term investments on the balance sheet at the fiscal year-end, shown for the fiscal years the market data feed covers because the older SEC record counts cash and equivalents alone. For Compass Therapeutics, Inc. it is on record here for 4 fiscal years, 2022 to 2025.
Fiscal years are named for the calendar year they end in.
Learn: cash on hand
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
Cite this page
Funkfolio, “Compass Therapeutics, Inc. (CMPX) cash on hand”, data as of 18 November 2026. https://funkfolio.com/stock/CMPX/cash
Underlying data: the company's filings with the SEC and Yahoo Finance.